Vaccines Market

Vaccines Market Size, Market Forecast and Outlook By FMI

The vaccines market was valued at USD 54.50 billion in 2025 and is projected to reach USD 111.3 billion by 2035. The market is set to register a 7.4% CAGR during the forecast period. Conjugate vaccines are expected to lead vaccine type with 24.7% share in 2025, while human use is likely to account for 68.2% share of the application segment.

Summary of the Vaccines Market

• Demand and Growth Drivers
  • Public immunization programs are expected to support wider vaccine access across pediatric and adult populations.
  • Government funding is likely to strengthen procurement and preparedness for infectious disease prevention.
  • Advanced vaccine platforms are anticipated to expand product pipelines for endemic and emerging diseases.
• Product and Segment View
  • Conjugate vaccines are expected to remain important due to broad use across national immunization schedules.
  • Human use is likely to lead application demand as governments prioritize disease prevention across age groups.
  • mRNA and recombinant platforms are anticipated to gain traction as manufacturers expand next-generation pipelines.
• Geography and Competitive Outlook
  • The United States is expected to lead listed country-level expansion due to strong biotechnology capacity and public health funding.
  • South Korea is likely to record steady demand as domestic vaccine manufacturing investment increases.
  • Companies with scalable manufacturing and advanced platform technologies are anticipated to strengthen market position.
• Analyst Opinion
  • Sabyasachi Ghosh, Principal Consultant for Healthcare at FMI, suggests, “The vaccines market is moving toward faster development cycles and more diverse technology platforms. Manufacturers with mRNA, recombinant, and cold-chain resilient capabilities are likely to gain advantage as public health systems expand preventive care.”
• Vaccines Market Value Analysis
  • The vaccines market is shifting from routine immunization supply toward broader preventive healthcare infrastructure.
  • Industry value is likely to rise as governments expand adult and pediatric vaccination programs.
  • Product adoption is expected to improve where conjugate and next-generation vaccines support stronger disease coverage.
  • Spending is anticipated to be supported by public-private partnerships and investment in manufacturing capacity.

Metric	Value
Market Size in 2025	USD 54.50 billion
Projected Market Size in 2035	USD 111.3 billion
CAGR (2025 to 2035)	7.4%

Analyzing Vaccines Market by Top Investment Segments

Conjugate Vaccines Leading the Technology Segment

In 2025, inactivated vaccines are anticipated to hold a 24.7% revenue share in the vaccines market. This segment’s strength has been attributed to their established safety profiles and proven immunogenicity across multiple disease areas. Regulatory approvals for these vaccines have consistently reflected strong efficacy data, supporting physician confidence and public acceptance.

Manufacturing scalability and the availability of standardized production protocols have facilitated consistent supply in both developed and emerging regions. Health authorities have endorsed these vaccines as foundational components of national immunization schedules, driving stable demand. Additionally, favorable storage requirements relative to some newer platforms have reinforced their widespread use in varied healthcare settings.

Human Use as the Dominant Application

Human use applications are projected to account for 68.2% of the vaccines market share in 2025. The segment has been reinforced by the prioritization of immunization programs aimed at reducing morbidity and mortality from infectious diseases across all age groups. Public health initiatives and funding commitments have been directed toward achieving high coverage rates in pediatric, adolescent, and adult populations.

Regulatory frameworks have provided strong support for accelerated approvals and procurement agreements to expand vaccine access. Consumer confidence has been bolstered by transparent safety monitoring and education campaigns. Pharmaceutical manufacturers have invested heavily in expanding production capacity and developing combination vaccines to streamline administration.

Challenges and Opportunities

Challenges

Supply chain gaps, vaccine hesitancy, and high development costs limit access and coverage.

Despite the rising demand, the constraints of the cold-chain hold back vaccine availability, especially in rural and remote areas. In many countries, vaccine hesitancy deriving from misinformation, religious ideology, or concerns about safety, is another significant barrier to universal coverage.

High R&D costs, complex and costly regulatory approvals, and the risk of clinical trial failure create a heavy burden on manufacturers. The cash-based model of services and limited healthcare infrastructure in low-income countries further limits the realization of potential immunization programs.

Opportunities

Personalized vaccines, mRNA platforms, and adult immunization drive future potential.

The future of vaccines will move toward precision immunization with the advancement of personalized or therapeutic vaccines being investigated for cancers, autoimmune diseases and allergies. Proven during the COVID-19 pandemic, mRNA technology is blooming to prevent influenza, RSV, and malaria.Similarly, adult and travel vaccination programs can be an opportunity, especially among aging populations and mobile workforces.

Thermostable and needle-free vaccines investments can vastly improve compliance as well as minimize bottlenecks in the distribution pipeline. And because AI has also helped in vaccine development, we will see a better digital immunization records.

Country-Wise Outlook

United States

The USA vaccines market continues to grow steadily due to strong immunization programs, advanced biotechnology capabilities, and high public health funding ,the cdc and hhs spend vast sums of time on routine vaccinations and preparedness for pandemic.

Increasing adoption of mRNA-based and combination vaccines for influenza, HPV and COVID-19 is moving technologies forward; Cold-chain warehouse storage, R&D, and manufacturing infrastructure are expanding in Massachusetts and Pennsylvania to satisfy rising domestic and international demand from major pharma companies.

Country	CAGR (2025 to 2035)
United States	6.7%

United Kingdom

In the UK, the development and deployment of vaccines are underpinned by robust public-private collaboration and centralized procurement through the National Health Service (NHS). The government funds rapid vaccine development platforms via the UK Vaccine Network and the Vaccines Manufacturing and Innovation Centre (VMIC).

The country is also focusing on multivalent and nasal vaccines for respiratory infections. It continues to drive the expansion of domestic production, driven by a strong demand for childhood immunisation coverage, seasonal flu vaccination as well as global demand for travel and export-oriented vaccines.

Country	CAGR (2025 to 2035)
United Kingdom	6.2%

European Union

New funding will be provided to expand the EU vaccines market, helping to implement new vaccine health- and economic policies and strengthen vaccine research and manufacturing resilience under the EU4Health programme within the scope of Horizon Europe. Vaccine production, especially for recombinant protein, mRNA, and viral vector platforms, is particularly concentrated in Germany, France, and Belgium.

European public health agencies are already able to co-operate with each other to make them better equipped for a pandemic make sure of vaccine coverage across borders. The European Centre for Disease Prevention and Control (ECDC) supports data-driven vaccination rollout, while policy initiatives around the European Immunization Agenda 2030 will underpin access and innovation.

Country	CAGR (2025 to 2035)
European Union	6.4%

Japan

Japan’s vaccines market is expanding at a time of an aging population, growing adult immunization awareness, and expanding domestic R&D. Japan's MHLW encourages investment in new vaccine technologies: MHLW in 2022 published draft Q&A in which it identified types of next-generation vaccines, including mRNA and cell-culture platforms.

Japan Is Boosting Its Vaccine Self-Sufficiency With New National Programs Incentivizing Local Production Of Pandemic And Seasonal Vaccines for pediatric and adult diseases such as pneumococcal infections, influenza, and shingles continue to top the high demand list. Export-oriented firms enter partnerships across Southeast Asia for regional immunization initiatives.

Country	CAGR (2025 to 2035)
Japan	6.1%

South Korea

The country is seeking to position itself as a global vaccine hub, investing in domestic mRNA platforms and cell-culture manufacturing . Cutting-edge companies are forging global pharmaceutical partnerships for clinical testing and manufacturing scalability.

Childhood immunization programmes are almost universal, and booster dose programmes for the older population are being scaled up. Local pandemic preparedness has been the focus of government efforts, prompting capacity-building for next-generation vaccine platforms and biologic supply chains.

Country	CAGR (2025 to 2035)
South Korea	6.6%

Competitive Outlook

The vaccines market is highly competitive and dynamic, driven by expanding immunization programs, pandemic preparedness initiatives, and ongoing R&D investment in novel vaccine platforms. Leading companies are prioritizing mRNA, viral vector, and recombinant protein technologies to accelerate development pipelines and respond to emerging infectious threats.

Strategic collaborations, government partnerships, and global supply agreements are central to scaling manufacturing and distribution capabilities. Additionally, focus areas such as thermostable formulations, combination vaccines, and equitable access in low- and middle-income countries are reshaping competitive strategies. Regulatory approvals and landmark product launches are intensifying rivalry, as companies aim to solidify leadership positions across pediatric, adult, and travel vaccine segments.

• In 2025, Moderna's new COVID-19 vaccine, mNEXSPIKE® (mRNA-1283), has received FDA approval. It's authorized for all adults 65+ and individuals aged 12-64 with underlying risk factors, as defined by the CDC. This expands vaccine options for vulnerable populations.
• In 2025, Pfizer and BioNTech have submitted a regulatory application to the EMA for COMIRNATY® for the 2025 to 2026 season. This updated COVID-19 vaccine targets the LP.8.1 strain, following the EMA's Emergency Task Force recommendation, and is based on BioNTech's mRNA technology.

Companies

• Sanofi SA
• Merck & Co., Inc.
• Pfizer BioNTech
• CSL Limited
• Johnson & Johnson
• Emergent Biosolutions Inc.
• AstraZeneca plc
• Mitsubishi Tanabe Pharma Corporation
• Serum Institute of India Pvt. Ltd.
• Bavarian Nordic A/S
• SINOVAC
• Novavax.
• Daiichi Sankyo
• Moderna, Inc.

Key Segmentation

By Vaccine Type:

• Inactivated
• Live attenuated
• Recombinant
• Toxoid
• Subunit & Conjugate

By Valance:

• Monovalent
• Multivalent

By Route of Administration:

• Injectable
• Oral

By Indication:

• Influenza
• Pneumococcal Diseases
• Human Papillomavirus
• Meningococcal Diseases
• Rotavirus
• MMR
• Hepatitis
• DTP
• Polio

By Distribution Channel:

• Hospital Pharmacies
• Institutional Sales
• Retail Pharmacies

By Region:

• North America
• Latin America
• Europe
• Asia Pacific (APAC)
• The Middle East & Africa (MEA)